AstraZeneca, Daiichi Sankyo and Summit Therapeutics launch three‑way trial of Datroway with ivonescimab
AstraZeneca, Daiichi Sankyo and Summit Therapeutics announced a clinical collaboration to evaluate Datroway (datopotamab deruxtecan) together with ivonescimab in multiple solid tumours. The partnership will begin with a Phase III study in first‑line triple‑negative breast cancer. Each partner will supply its own drug, share trial costs and retain development and commercial rights. AstraZeneca has also committed a US$2 billion equity investment in Summit to support the combination programmes.
Why it matters
The collaboration expands the pipeline of all three companies into new tumour indications, potentially driving future revenue if the combination proves effective. AstraZeneca’s $2 billion investment signals confidence in ivonescimab and may boost Summit’s valuation, while Daiichi Sankyo gains a partner to co‑develop its Datroway ADC.
Key facts
- 1The three companies announced the collaboration on 2 Oct 2026. tradingview.com
- 2The partnership will start with a Phase III trial in first‑line triple‑negative breast cancer. tradingview.com
- 3Each company will contribute its own medicine, share trial costs and retain development and commercial rights. tradingview.com
- 4AstraZeneca announced a US$2 billion equity investment in Summit to support combination studies. mugglehead.com
- 5Ivonescimab is approved in China for non‑small cell lung cancer and a BLA is under FDA review for EGFR‑mutated NSCLC. biopharminternational.com
- 6Datroway is approved in more than 30 countries for TNBC and in more than 45 countries for HR‑positive, HER2‑negative breast cancer. biopharminternational.com
Summary written by AlphAI from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.